EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Case series profile of olanzapine post‐injection delirium/sedation syndrome

Jason Seebaluck, Michael A Downes, Jared Brown, Keith Harris, Katherine Z Isoardi, Betty S Chan iD

British Journal of Clinical Pharmacology · 2023-02 · 89 (2) · 903-907

DOI: 10.1111/bcp.15588 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 20.11.2022. Verfasst von Jason Seebaluck und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine & Clinical Toxicology, Prince of Wales Hospital, Randwick, NSW, Australia. Hauptthemen laut MEDLINE: Antipsychotic Agents, Delirium. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Olanzapine pamoate is an intramuscular depot injection for the treatment of schizophrenia. Approximately 1.4% of patients develop a serious adverse event called post‐injection delirium/sedation syndrome (PDSS), characterised by drowsiness, anticholinergic and extrapyramidal symptoms. The objective is to investigate olanzapine PDSS presentations including clinical features and treatment approach. This is a retrospective review of olanzapine PDSS patients from three toxicology units and the NSW Poisons Information Centre between 2017 and 2022. Adult patients were included if they had intramuscular olanzapine then developed PDSS criteria. Clinical symptoms, treatment, timing and length of symptoms were extracted into a preformatted Excel database. There were 18 patients included in the series, with a median age of 49 years (interquartile range [IQR]: 38–58) and male predominance (89%). Median onset time post injection was 30 min (IQR: 11–38). PDSS symptoms predominate with drowsiness, confusion and dysarthria. Median length of symptoms was 24 h (IQR: 20–54). Most common treatment included supportive care without any pharmacological intervention ( n = 10), benzodiazepine ( n = 4) and benztropine ( n = 3). In one case, bromocriptine and physostigmine followed by oral rivastigmine were given to manage antidopaminergic and anticholinergic symptoms respectively. This proposed treatment combination could potentially alleviate some of the symptoms but needs further studies to validate the findings. In conclusion, this case series supports the characterisation of PDSS symptomology predominantly being anticholinergic with similar onset (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsDeliriumAdultHumansMaleMiddle AgedFemaleOlanzapineBromocriptinePhysostigmineRivastigmineBenzodiazepines

Stichwörter der Autor:innen

PDSSdepot antipsychoticdrug reactionolanzapine pamoateschizophrenia

Substanzen

OlanzapineAntipsychotic AgentsBromocriptinePhysostigmineRivastigmineBenzodiazepines

Autor:innen und Institutionen

  • Department of Emergency Medicine & Clinical Toxicology, Prince of Wales Hospital, Randwick, NSW, Australia.
  • Clinical Pharmacology & Toxicology Unit, Calvary Mater Newcastle Hospital, Waratah, NSW, Australia.
  • New South Wales Poisons Information Centre, Children's Hospital at Westmead, Westmead, NSW, Australia.
  • Clinical Toxicology Unit, Princess Alexandra Hospital, Woolloongabba, QLD, Australia.
  • Medicine and Health, University of New South Wales, Kensington, NSW, Australia.

ORCID-Profile: Betty S Chan

Zitieren

APA

Seebaluck, J., Downes, M. A., Brown, J., Harris, K., Isoardi, K. Z., & Chan, B. S. (2023). Case series profile of olanzapine post‐injection delirium/sedation syndrome. British Journal of Clinical Pharmacology, 89(2), 903-907. https://doi.org/10.1111/bcp.15588

Vancouver

Seebaluck J, Downes MA, Brown J, Harris K, Isoardi KZ, Chan BS. Case series profile of olanzapine post‐injection delirium/sedation syndrome. British Journal of Clinical Pharmacology. 2023;89(2):903-907. doi:10.1111/bcp.15588

BibTeX
@article{Seebaluck2023,
  author = {Seebaluck, Jason and Downes, Michael A and Brown, Jared and Harris, Keith and Isoardi, Katherine Z and Chan, Betty S},
  title = {Case series profile of olanzapine post‐injection delirium/sedation syndrome},
  journal = {British Journal of Clinical Pharmacology},
  year = {2023},
  volume = {89},
  number = {2},
  pages = {903--907},
  doi = {10.1111/bcp.15588}
}
Kostenlos starten →